*contains promoted content

Good morning, Folks, Jeff Bishop here,

It’s no secret that AI has been the talk of Wall Street for the last several years.

As a result, every Tom, Dick, and Harry is chasing AI stories that are already crowded…

The companies that everyone on CNBC is talking about.

But every so often, Wall Street discovers a smaller company before the broader market does.

That's why I want to show you something this morning.

On Monday, an analyst firm initiated coverage on a little-known AI company with a Buy rating and a $10 price target.

At yesterday's close, that target represented more than 33% upside.

What's interesting is that this isn't some pre-revenue AI startup promising to change the world. There are plenty of those.

This company generated roughly $73 million in trailing revenue as of mid-2025, and management projects approximately $82.5 million for this fiscal year.

Its operations already span seven countries, and it employs nearly 800 people.

Its market cap has crossed $1.5 billion, yet many U.S. investors have probably never heard of it.

Not the typical “micro-cap stock” I usually look for, but this is a unique situation.

You can see why I think this story is worth watching right here.

The company is building what it calls an AI-powered "living infrastructure" platform.

In plain English, it wants to become the operating system behind some of the biggest transactions and services people use throughout their lives.

Finding a home. Moving. Utilities. Insurance. Banking. Home services. And much more.

Recently, the company announced a series of partnerships and expansion initiatives aimed at markets measured not in billions, but trillions.

One announcement targeted a global residential services market estimated at more than $3 trillion.

Another company expanded its footprint into a market worth more than $94 billion.

A third opened the door to a major segment of the U.K. residential services industry.

Again, all of this happened within the past several weeks.

You can review the full story here. 👈

This isn't a one-trick AI company.

Alongside its property technology business, it also operates an ag tech division deploying precision agriculture drones and connected devices.

In other words, investors are getting exposure to multiple AI-driven growth markets under one roof.

The market is constantly looking for the next AI story. Sometimes those opportunities are obvious…

Other times they are hiding in plain sight until analysts, institutions, and momentum traders begin connecting the dots.

I think this is one of those situations.

Have a look and see what you think.

To Your Success,

P.S. Come check out our momentum stock chat room - the doors are open to all!

*together with Simpler Trading

Good evening, everyone!

As you opened my email from Saturday, I’m sending this out as a reminder to join John Carter tomorrow night (6pm Central, 7pm EST).

Here's something most trading courses skip right over.

Professional traders don't just have better charts. 

They have better information.

There's data that shows what the biggest players on Wall Street are doing with their money before it shows up on any standard chart. It shows when they're loading up on a sector and when they're quietly betting against a move that looks great on paper.

Most retail traders never see it. The charting platforms don't offer it.

John Carter got an edge by getting access to this intel…

And he’s been using it for years… .

He spent three decades refining his research process around that data…

And it helped him produce 10 seven-figure trades, including $5.2 million on a single Google position (per Simpler Trading).

His chart and that data had to point the line up before he'd bet big.

(We’re not sharing this to brag, but to show John knows a thing or two about high-level trading! Please note that trading is hard and results like his are not guaranteed or typical.)

Listen, most retail traders may never have that kind of edge… 

Until now.

John built an AI to turn all this proprietary data into distilled trading ideas….

Every evening his AI Trading Intelligence runs his full research process. 

The top trade ideas are automatically delivered to a private dashboard with exact entries, targets, and stops already defined.

Word has gotten out that John’s AI is finally going to be available to members of his trading community.

John is showing the whole system live on June 17th at 7pm EST for the very first time.

The good news is that because you’re one of our loyal subscribers, you can also attend live…

Use this link to secure your spot.

P.S. This is the first time John has ever shown this system publicly. Be sure to attend LIVE because there might not be a replay

(By the way, I was happy to host John a few months back, he’s a trading LEGEND - and especially resonates with seasoned pros!)

*contains promoted content

Good morning, Folks,

Yesterday was another reminder of why we spend so much time digging through the small-cap market.

If you saw in your inbox, I sent you two emails.

One of those ideas surged nearly 14% intraday.

Another exploded by as much as 43% during the day, then settled down and finished the day up around 20%.

Not every idea works.

But when a small company catches the market's attention, the gains can come fast.

This morning, I've got another one for you.

It's a Nasdaq-listed company that just reported that its April sales jumped nearly 300% year over year.

Not website traffic. Not app downloads. Not "engagement”...

Actual sales.

And that came after first-quarter revenue surged 114%.

It’s not even selling some hyped up AI product.

The company has a commercial product being used by physicians today.

In fact, adoption appears to be accelerating: Ordering physicians increased 69%. Unit sales climbed 146% in the first quarter.

The company has also launched a 2,000-patient study involving VA medical centers, military hospitals, and academic institutions.

Meanwhile, one of the most closely watched events on its calendar is scheduled for today.

It’s a panel of doctors that’s set to discuss real-world results from the company's technology and how it is changing clinical decision-making.

The market opportunity is enormous, while the valuation is still tiny. And the news drops have been relentless.

That's the momentum I look for on “tactical trade” opportunities.

I've put together a full breakdown, including the company name, recent catalysts, and what traders are watching heading into today.

Click here to see the complete overview I have put together.

We'll see what happens when the opening bell rings, but only if you get this one on your radar before things start moving.

See my full report right here.

To Your Success,

*Disseminated on behalf of Banzai International

Explosive Revenue Growth, Expanding SaaS Margins, and Rising Earnings Estimates Put BNZI at the Center of a Powerful AI-Driven Growth Story!

Hi All,

Banzai International (NASDAQ: BNZI) is attracting renewed investor attention following its recent Zacks Rank #2 (Buy) upgrade, a signal driven by improving earnings estimate revisions and growing analyst confidence.

While first-quarter revenue remained relatively stable at $2.7 million, management continues to focus on improving operational efficiency, strengthening the balance sheet, and expanding the company's AI-powered sales and marketing platform. 

Recent initiatives—including a $5.5 million annualized cost reduction program, significant debt reduction efforts, and the proposed acquisition of ConnectAndSell—highlight management's strategy to improve profitability while positioning the business for future growth.

With gross margins remaining above 80%, an expanding customer base of more than 150,000 users, and new distribution opportunities through strategic partnerships, BNZI is building the foundation for what investors hope could become a larger AI-powered revenue platform!!

ZACKS BUY RATING DRIVES NEW INVESTOR ATTENTION

One of the most notable recent developments for BNZI is its upgrade to a Zacks Rank #2 (Buy). The Zacks ranking system is heavily driven by changes in earnings estimate revisions, a factor widely regarded as one of the strongest indicators of potential near-term stock performance.

The upgrade reflects increasing analyst confidence in BNZI's business trajectory as forecasts continue moving higher. Historically, improving earnings expectations have often preceded increased institutional interest and valuation expansion.

As BNZI continues to execute against growth objectives, the positive earnings revision trend may serve as an important signal that broader market recognition is beginning to emerge.

MANAGEMENT TAKES ACTION TO IMPROVE PROFITABILITY

In May, BNZI announced a company-wide operating cost reduction initiative expected to improve operating profits by approximately $5.5 million on an annualized basis.

Management expects these actions to reduce operating cash burn by roughly 40% while maintaining planned revenue growth initiatives.

Key actions include:

• Reducing reliance on outside consultants

• Lowering professional services expenses

• Centralizing financial systems and processes

• Selective workforce optimization

The majority of these measures have already been implemented, with the full impact expected to be reflected in operating expenses during the third quarter.

For investors, the announcement represents a meaningful step toward improving financial efficiency while preserving growth initiatives.

STRONG GROSS MARGINS HIGHLIGHT SAAS SCALABILITY

Despite revenue headwinds during the first quarter, BNZI maintained strong software economics.

The company reported first-quarter gross margin of approximately 80.7%, following gross margin of 81.9% during the fourth quarter of 2025.

High gross margins are often viewed as a critical characteristic of scalable software businesses because they provide flexibility to invest in growth while improving long-term profitability potential.

As management continues implementing cost reduction initiatives, investors may focus increasingly on operating leverage and margin performance as key indicators of progress.

BALANCE SHEET IMPROVEMENTS STRENGTHEN FINANCIAL POSITION

BNZI made meaningful progress strengthening its balance sheet during the first quarter.

The company reduced debt by approximately $4.5 million during the quarter and reported total debt reduction of approximately $7.4 million year-to-date.

Management also converted approximately $3.8 million of debt into equity and raised additional capital through financing programs designed to support future growth initiatives.

These actions provide greater financial flexibility as the company continues executing on its operational and strategic objectives.

STRATEGIC ALLIANCE WITH INGRAM MICRO EXPANDS DISTRIBUTION REACH

A major catalyst announced during the quarter was BNZI's strategic alliance with Ingram Micro.

The agreement provides distribution access for Banzai's OpenReel and Demio platforms through Ingram Micro's extensive network of technology channel partners throughout the United States.

Management believes the partnership can accelerate adoption among enterprise customers seeking AI-powered engagement, virtual event, and video production solutions.

The relationship also creates a framework that could support future BNZI products as the company's platform continues to evolve.

CONNECTANDSELL ACQUISITION COULD EXPAND AI PLATFORM CAPABILITIES

BNZI recently signed a non-binding letter of intent to acquire the assets of ConnectAndSell.

If completed, the transaction is expected to expand both the company's revenue opportunities and its AI-powered platform capabilities.

The proposed acquisition would extend BNZI's reach beyond marketing technology into sales engagement and revenue acceleration, helping create a more comprehensive platform that supports businesses throughout the customer acquisition and conversion process.

Management believes the addition could increase annual revenue while broadening the company's addressable market.

ENTERPRISE FOCUS AND CUSTOMER SCALE REMAIN KEY ASSETS

BNZI's customer base now exceeds 150,000 organizations and users that have purchased or subscribed to company products.

This broad customer footprint provides opportunities for:

• Recurring revenue generation

• Cross-selling additional products

• Enterprise account expansion

• Increased customer lifetime value

Management has indicated that growing enterprise adoption remains a key strategic priority as the company works to deepen customer relationships and expand into higher-value market segments.

Multiple Catalysts Are Beginning to Align

BNZI appears to be entering a potentially important stage of its growth story as several positive developments converge:

• Zacks Rank #2 (Buy) upgrade

• Rising earnings estimates

• $5.5 million annualized cost reduction initiative

• Strategic alliance with Ingram Micro

• Expansion into a broader AI revenue platform

• Growing enterprise adoption

While execution remains critical, BNZI is increasingly demonstrating a combination of growth, scalability, operational discipline, and strategic expansion that is attracting renewed attention from investors.

As earnings revisions trend higher and management continues executing on growth initiatives, BNZI may remain a company worth monitoring as its market profile continues to evolve!

*contains promoted content

Hey Folks, Jeff Bishop here,

Over the last few weeks, I've been monitoring a biotech that’s reinventing itself in real time.

Two months ago, shares were trading below $5.

As of Friday’s close, they're up roughly 390%.

Something must be going on…

It turns out that the events that fueled the rally all happened within a very short period of time.

👉 A milestone $7.5 million payment from a major pharmaceutical company.

👉 A new Phase 2 asset added to the pipeline.

👉 A new CEO with experience at AbbVie, Gilead, and Amgen.

👉 A $30 million financing.

👉 A board overhaul.

And several potentially important clinical milestones still coming down the tracks.

👉 I've Put Together the Full Timeline Here 👈

Most small biotech companies spend years trying to assemble the pieces this company put together in a matter of weeks.

And the market has clearly noticed — to the tune of nearly 400%.

But here's what has my attention now...

The lead asset the company acquired is already in Phase 2 development, and management expects key data in the second half of this year.

And that’s just one of several milestones that are expected before year end.

👉 See Why Traders Are Watching The Next Chapter Here 👈

And then there's the new CEO.

Her career includes helping build blockbuster immunology franchises and leading biotech companies through major growth phases.

Executives with that background don't usually leave established positions for situations they believe are stagnant.

So the question becomes:

What exactly does she see here?

I've broken down the recent developments, the upcoming catalysts, and  everything I’m watching on the full research page right here.

To Your Success,

*together with Simpler Trading

Hey Folks, happy weekend. Hope you’ve had time to gather your druthers after such a crazy market week!

On that note, can you relate to this???

You pick a trade. The chart looks PERFECT.

It fails anyway.

Here might be why...

There's a whole layer of information behind every chart that most trading platforms never show you. It reveals what the biggest players on Wall Street are doing with their money before it shows up anywhere else.

When that information lines up with a setup, the trade moves.

When it doesn't, even the best looking setup can backfire.

John Carter gained access to that data and discovered how to exploit it… 

He’s been trading for almost 30 years. And he’s using data and tools most traders never see.

According to Simpler Trading, Carter has generated multiple seven-figure trades during his career, including a big bet on Google that produced approximately $5.2 million in 3 weeks. 

It’s the same story behind every one of his 10 seven-figure trades.

(We’re not sharing this to brag, but to show John knows a thing or two about high-level trading! Please note that trading is hard and results like his are not guaranteed or typical.)

Listen, most traders never get that information. 

Their platforms don't show it.

That’s why John built an AI trading intelligence that now runs his entire nightly research process automatically. It’s checking everything he checks, every single evening. 

His top trade ideas appear in his dashboard before the market opens. Already graded A+ to F. Ready to act on.

This is cutting edge. 

In fact, no one outside of John’s inner circle has even seen this yet…

John’s hosting a private training for his members on Wednesday, June 17th at 7pm EST. 

He's showing us the whole system for the first time.

John gave us a link for our subscribers to register for the live demonstration…

To see it for yourself, use this link to secure your spot

No obligation of course, just give it a look!

P.S. During the live session, John will walk through current trades and show you both the chart AND the data behind it. You'll see exactly what he sees when he decides to bet big. 

(By the way, I was happy to host John a few months back, he’s a trading LEGEND - and especially resonates with seasoned pros). So make some time to join him on Wednesday.)

 *Disseminated on Behalf of U.S. Gold Corp.

Billionaires Are Buying USAU—Here’s Why This Tiny U.S. Gold & Copper Powerhouse Could Be the Next Mining Mega-Winner! 

A Fully Permitted NASDAQ Microcap May Be Quietly Becoming the Hottest Critical Minerals Play on Wall Street!

Greetings All,

Smart Money Is Rotating OUT of Tech and INTO Dirt (Literally)!

There’s a quiet capital rotation happening right now—and it’s not going into AI hype cycles or overextended tech multiples. It’s flowing into hard assets: gold, copper, and U.S.-based critical minerals.

With geopolitical tension rising, fiat currency trust weakening, and governments scrambling to secure domestic supply chains, investors are re-pricing one thing fast: resource security matters again.

That’s where U.S. Gold Corp. (NASDAQ: USAU) enters the chat—not as a speculative explorer, but as a fully permitted, development-ready U.S. gold-copper producer sitting at the exact intersection of policy tailwinds and commodity supercycles.

This isn’t “hope and drill results.” 

This is shovels-ready infrastructure with federal momentum behind it.

USAU — The Fully Permitted Sleeper That Wall Street Is Starting to Notice

Let’s be clear: USAU isn’t your typical junior miner endlessly burning cash on early-stage drilling.

It’s a development-stage gold and copper company with its flagship CK Gold Project in Wyoming already fully permitted and construction-ready.

Translation? No years of waiting. No regulatory roulette. No “maybe someday” pipeline.

The CK Gold Project already carries:

• ~1.0–1.6 million ounces of gold + 260M lbs copper 

• ~85,000–110,000 ounces annual gold-equivalent production potential 

• ~11-year mine life 

• Low strip ratio (~0.98:1) and infrastructure-rich location near Cheyenne 

• Estimated ~$394M initial capex with strong projected economics even under conservative pricing 

At higher gold assumptions, projected NPV scenarios scale aggressively—turning what looks like a modest mid-tier project into a cash-flowing machine in waiting.

This is why analysts are throwing out targets like $16.50, $22, and even $27.50 per share!

The Billionaire Signal — Why “Smart Money” Is Quietly Circling USAU

When names like Eric Sprott show up on the shareholder list, markets tend to pay attention later… and regret not paying attention earlier.

USAU’s investor base includes:

• Resource legend Eric Sprott 

• Franklin Templeton 

• Mackenzie Investments 

• Terra Capital Natural Resources Fund 

• Other institutional and strategic holders across the mining ecosystem 

This isn’t retail hype—this is institutional conviction in a domestic critical minerals story with actual execution visibility.

And here’s the key signal: insiders and large capital allocators don’t pile into companies waiting for “potential.” They position for permits, feasibility, and financing pathways already in motion.

USAU checks all three.

CK Gold — The Rare “Build-It-Now” Asset in a Sea of Promises

The CK Gold Project isn’t theoretical anymore—it’s engineered, permitted, and practically waiting for financing to break ground.

Recent feasibility work outlines:

• 11-year mine plan 

• ~20,000 tons/day processing capacity 

• Dry-stack tailings design (modern ESG-aligned mining) 

• Updated metallurgy and processing flowsheet improvements 

• Road, power, and water access already in place 

• Wyoming jurisdiction = low sovereign risk, mining-friendly state 

Even more interesting: management has flagged additional upside beyond the current mine plan, including:

• Resource expansion outside the reserve model 

• Potential aggregate sales (turning “waste rock” into revenue) 

• Higher recovery optimization opportunities 

• Possible future exploration extensions nearby 

This isn’t a static mine—it’s a platform asset with multiple monetization layers.

Policy Tailwind — The Trump-Era Critical Minerals Push Changes Everything

One of the biggest underappreciated catalysts here is macro policy.

The U.S. government has been aggressively prioritizing:

• Domestic gold and copper production 

• Reduced reliance on foreign mineral supply chains 

• Faster permitting pathways via federal dashboards 

• Strategic critical mineral security frameworks 

That matters because USAU is already where most companies want to be—fully permitted and U.S.-based.

In a world where permitting delays can kill a decade of value creation, USAU’s biggest advantage might simply be this:

It’s already cleared the bureaucratic runway.

Why Investors Are Starting to Pay Attention NOW

Here’s the asymmetric setup:

• Fully permitted project ✔ 

• Institutional and billionaire ownership ✔ 

• Feasibility study complete ✔ 

• Financing discussions underway ✔ 

• Construction timeline targeting mid-cycle execution ✔ 

• Analysts projecting significant upside range ✔ 

Meanwhile, the broader backdrop is screaming:

• Gold strength in macro uncertainty 

• Copper demand rising from electrification 

• Domestic resource security becoming national priority 

The Bottom Line

USAU Is No Longer Just a Mining Stock — It’s a Policy-Backed, Permitted, Institutionally-Supported Optionality Play!

U.S. Gold Corp. (NASDAQ: USAU) is transitioning from overlooked microcap to fully permitted, construction-stage critical minerals candidate with multiple catalysts aligned at once: financing, development, and macro policy support.

In a market obsessed with digital illusions, USAU is positioned in something far more tangible:

real ounces, real copper, real land, real infrastructure—and real demand from governments and industry.

The story now isn’t whether USAU exists on the radar. It’s how long it may stay underappreciated before the market fully prices in what’s already been built.

P.S. Come check out our momentum stock chat room - the doors are open to all!

(ENTER THE CHAT ROOM)

*contains promoted content

Hey Folks, Jeff Bishop here,

Before the bell, there’s a small Nasdaq company that just put out one of the more interesting updates I’ve seen in this market.

This company operates an 80+ acre environmental processing facility in Florida.

Unlike so many small Nasdaq companies, this is not a pre-revenue story.

And we’re not talking about a YOLO ticket on a sketchy AI stock.

Instead, the company operates an established facility with 117 active commercial customers, and on June 2, it announced a record operating quarter.

Its resource group delivered 65,572 cubic yards of finished mulch, compost, and wood products in Q1 — up about 57% from the prior quarter.

An independent drone survey just verified roughly 184,700 cubic yards of material on-site.

👉Get The Full Story Here Before The Opening Bell👈

As you would expect, revenue is moving too.

Q1 consolidated revenue came in at $3.96 million, up roughly 20.5% from Q4.

Materials sales grew about 44% quarter-over-quarter.

And the company’s logistics segment turned profitable for the first time.

I’ll be the first to admit that mulch and compost aren’t the sexiest revenue lines, but who can deny that momentum?

But the bigger story may still be ahead.

The company expects to commission a new mill in the second half of 2026, which, by my reckoning, should be before the end of the month.

The mill is designed to turn oversized organic material into a higher-margin engineered substrate product, which could open the door to a much larger market.

For an idea of what’s at stake, the global soil amendments market is estimated around $19.6 billion, with the company citing projected growth of 11.2% annually through 2030.

So you have a tiny Nasdaq company…

⭐ With record deliveries…

⭐ Accelerating revenue…

⭐ A profitable logistics segment…

⭐ And a new mill catalyst is expected imminently…

👉 Click Here To See The Tactical Trade Idea 👈

This is the type of situation traders can completely miss until the story starts spreading.

And by then, the easy move may already be gone.

Click right here to start your homework now.

To Your Success,

*together with BioStem Technologies, Inc. 

There’s a Good Reason to Watch BSEM Closely After Its Strategic Reset Quarter — And Why the Company’s Expanding Hospital Footprint, Clinical Momentum, and Nasdaq Uplisting Path Could Still Signal Significant Upside Ahead!

The latest quarterly report from BioStem Technologies (OTCQB: BSEM) entered may have reflected short-term pressure from acquisition integration costs and margin transition dynamics, but many experienced growth investors are looking beyond the temporary earnings volatility and focusing instead on the broader transformation now underway. 

Following the BioTissue acquisition, BSEM dramatically increased its commercial reach, accelerated its entry into hospital-based wound care markets, expanded its sales infrastructure, and continued building what management believes can become a fully integrated regenerative medicine platform spanning both chronic and acute wound care applications.

At the same time, BSEM continues to operate in some of healthcare’s fastest-growing sectors, including diabetic wound care, surgical recovery, soft tissue repair, and advanced biologic therapies. 

With prior profitability already demonstrated over multiple quarters (seven actually) proprietary allograft technology differentiating the company from competitors, and analysts citing the potential for substantial valuation expansion if execution continues, speculative investors are increasingly keeping the company on high-alert watchlists throughout 2026. 

As BSEM continues progressing toward a planned Nasdaq uplisting, investors are closely watching the company for the possibility of increased market visibility, stronger liquidity, and expanded institutional interest. 

Adding to the bullish sentiment, Zacks Small-Cap Research has previously issued a $25.50 price target on BSEM, highlighting the company’s profitability track record, clinical momentum, and long-term growth opportunity in regenerative medicine and advanced wound care!

Discover why BSEM is emerging as one of the most intriguing regenerative medicine transition stories currently developing in the OTC market

*Disseminated on behalf of Conexeu Sciences Inc.

You’ve seen it on celebrities, athletes, politicians — maybe even a few of your friends.

They suddenly take on the sunken, wrinkled appearance of someone ten or twenty years older. Their cheeks hollow out. Their skin looks deflated. Their face seems to collapse inward.

But they haven’t aged.

They’ve just started using a GLP‑1 drug like 0zempic, Wegovy or Mounjaro… and while they’re losing weight at record speed, they’re also winding up with what many are now calling “0zempic face.”

And now many are looking for a solution to this emerging issue.

As a result, some individuals affected by 0zempic face are spending significant amounts on treatments such as Botox, fillers, hyaluronic acid and biostimulators, as they try to get back to looking like themselves.

In fact, according to the Boston Consulting Group the revenue generated for these treatments thanks to GLP-1 side effects will more than double over the next five years to $2 billion.

But here’s the issue… when it comes to 0zempic face, these products — which are often used to address wrinkles — may not offer a long-term solution for everyone.

They may add volume to the skin for a period of time, but they are not designed to rebuild tissue affected by rapid weight l*ss.

That has created a potentially significant market for new products intended to address 0zempic face.

But here’s what’s most important for you as an investor:, my research has uncovered a little known company with a breakthrough technology that could change everything. 

The company is called Conexeu Sciences (Nasdaq: CNXU), and it has developed a regenerative technology designed to support facial tissue and help address the appearance of 0zempic face.

As word begins to spread about Conexeu’s flagship product, known as CXU™, the company may be positioned to participate in this developing market.

My name is Robert Kiyosaki, author of Rich Dad, Poor Dad. 

In recent years, I’ve devoted myself to helping ordinary investors identify major market trends — before they become obvious to the general public — so they can potentially reap the rewards that come from getting an early jump on those trends.

My analysis shows that treating 0zempic face is rapidly becoming one of those trends… as more and more people jump on the GLP-1 bandwagon, and then find themselves searching for ways to fill out their face.

Conexeu’s technology may be well suited to this task — and appears different from many products currently on the market… providing structural support intended to help users address changes associated with GLP-1-related facial volume loss.

With many people around the world taking GLP-1 drugs, this company and its proposed solution may be worth watching.

To give you the full story, I’ve written a new Special Report with everything you need to know about Conexeu Sciences (Nasdaq: CNXU).

It’s called The Tissue Wall Street Can’t Print, and it reveals all the reasons why I’m so excited about this unique company’s potential, it’s unique technology, and the investment opportunity it could turn out to be.

To get your free, no-obligation copy of this $199.95-value Report, click here, and you can download it immediately.

According to my research and analysis, Conexeu Sciences (Nasdaq: CNXU) could offer investors exposure to an emerging sector focused on helping people address 0zempic face.

I’m already recommending that subscribers to my Kiyosaki Letter take a closer look at the company and undergo their own due diligence process in relation to the company. I recommend you do the same.

Click here now to download your free Special Report.

Regards,

Robert Kiyosaki, Editor

The Kiyosaki Letter

*Disclaimer: Robert Kiyosaki is not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Conexeu Sciences Inc. has paid Robert Kiyosaki a fee of $125,000 as consideration for marketing services to be provided over a term of 90 days. [Robert Kiyosaki is a non-arm's-length party who owns zero common shares of Conexeu Sciences Inc.] This newsletter is for informational purposes only. This does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it constitute investment, legal, or tax advice. Prospective investors should consult qualified legal, financial, and tax advisors before making any investment decision. The securities issued by the companies we profile should be considered high risk. If you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEC and SEDAR+ filings, press releases, and risk disclosures. We also recommend reviewing any applicable prospectus or offering memorandum filed by the company. The information contained in this newsletter was obtained from the company directly, as well as from SEC and SEDAR+ filings, company websites, and other publicly available sources. While we believe such information to be accurate and reliable, we cannot guarantee its accuracy and prospective investors should conduct their own due diligence.

Forward Looking Statements

This newsletter includes certain statements that may be deemed “forward looking statements”. All statements in this newsletter, other than statements of historical facts, that address events or developments that Conexeu Sciences Inc. (the “Company” or “CXU”) expects to occur, are forward looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.

Forward-looking statements include, but are not limited to, statements regarding:  the Company's plans to seek regulatory clearance or approval for its CXU™ product candidates across its target indications, including wound care, dental soft tissue regeneration, veterinary wound care, and medical aesthetics; the Company's anticipated timelines for regulatory submissions, clinical programs, and commercial market entry across its target verticals; the Company's belief that its regulatory strategy will compress timelines and reduce costs relative to alternative regulatory pathways; the Company's expectation that its CXU™ platform is designed to extend across multiple indications from one core formulation; the Company's expectation regarding the manufacturing, storage, and logistical advantages of its product format, including ambient storage capability, point-of-care reconstitution, and global scalability; the Company's beliefs, based on preclinical data, regarding the performance characteristics and clinical potential of its CXU™ product candidates; the Company's expectation regarding its competitive positioning and potential in the medical aesthetics and regenerative medicine markets; and the Company's estimates regarding the size of the total addressable markets across its target verticals.

Forward-looking statements are subject to a variety of known and unknown risks, uncertainties, and other factors that could cause actual events or results to differ from those expressed or implied. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Certain important factors that could cause actual results, performance or achievements to differ materially from those in the forward-looking statements include, among others: additional capital requirements; inability to obtain sufficient funding; no history of commercial operations; no operating revenues; global financial conditions; regulatory risks, including the risk that applicable regulatory authorities do not grant clearance or approval for the Company's product candidates on anticipated timelines or at all; risks related to research and development activities and the uncertainty of their outcomes; manufacturing and supply chain risks; intellectual property risks; commodity markets; insured and uninsured risks; health, safety and community relations; environmental risks and hazards; currency rate risk; infrastructure; competitive industry environment; government regulation; management and organizational growth; climate change and climate change regulations; risk of litigation; reliance on key personnel; internal controls; conflicts of interest; interest rate risk; credit risk; liquidity risk; risks related to commercialization of the Company's products, including market acceptance, pricing, and reimbursement risks; competition from existing and new market entrants; and uninsurable risks.

Preclinical Status

The CXU™ device candidate is investigational. Statements regarding its mechanism, performance, or potential are based on preclinical findings; clinical significance has not yet been established. The Company has applied to pursue FDA clearance through the 510(k) pathway as a Class II device. There can be no assurance that the Company will obtain clearance on its anticipated timeline, or at all.

*contains promoted content

Hey Folks, Jeff Bishop here,

The SpaceX IPO will dominate headlines this week, and for good reason.

With a reported valuation approaching $1.75 trillion, it will mark one of the largest and most anticipated public offerings in market history.

The space economy will be at the top of everyone’s minds, and that's exactly why I've been digging into today's “tactical trade” idea.

While this company is dramatically smaller than SpaceX, it operates in the same broad market, and its shares have already surged more than 60% over the past few weeks.

👉 Click Here To See Today's Tactical Trade Idea 👈

This company operates directly from NASA's Kennedy Space Center.

It owns what appears to be the only commercial Mach 2 fleet in the world, and its customer list includes major aerospace and defense organizations.

Recently, two senior leaders from Blue Origin joined the company's leadership team.

And just days ago, the company announced it had been selected for inclusion in the Russell 3000 Index — putting it on the radar of funds tracking ~$12.2 trillion in assets.

The company has an interesting approach to launching payloads into space…

Most people think about massive rockets launching from fixed ground facilities. 

This company is pursuing something entirely different.

Management is developing an airborne launch platform designed to help deliver smaller payloads and satellites into orbit.

According to the company, the goal is to offer a flexible and cost-competitive alternative in one of the fastest-growing areas of aerospace.

And the opportunity could be enormous…

Industry forecasts suggest the small satellite market could more than triple over the next several years.

Meanwhile, thousands upon thousands of satellites are expected to be launched this decade.

If those projections prove accurate, the companies serving this market could see significant demand.

👉 Click Here To See Why This Stock Has Been Climbing Higher 👈

With SpaceX going public this week, the space economy will be at the top of everyone’s minds… 

This stock has already moved 60% recently, and I’ll be watching closely today to see if that momentum keeps up.

To Your Success,

P.S. Come on into our free small cap chat room OPEN NOW!

(ALL are welcome - Join the best trading community today!)

Happy weekend Folks, but no time to rest for traders, it’s time to lock in!

As excitement builds around the upcoming SpaceX IPO, I’ve been taking note of the chatter and the concern out there. Maybe investors should think twice?

Here’s a few warning signs that keep arising that deserve closer scrutiny.

What’s Up with Fidelity?

First, why is SpaceX reportedly allocating an unusually large portion of its IPO to retail investors? According to public reports, retail investors may receive up to 30% of the offering, far above the typical 5–10% allocation seen in most IPOs. 

Traditionally, the most sought-after IPOs are heavily oversubscribed by institutional investors.

Further, Fidelity is opening the SpaceX IPO to any customer with at least $2,000 in a retail brokerage account, down from as much as $500,000 for previous offerings (Muskonomy on X).

For perspective, even with seven~figure accounts, most people can't usually get access to IPOs that they want. 

That raises some obvious questions: Is this simply an effort to democratize access, or does it reflect a need to broaden the buyer base beyond institutions? If institutional demand is as strong as many believe, why make such an unusually large allocation available to retail investors?

Maybe it’s not as strong as we’re led to believe 🤔. 

What’s Up with Google (and Anthropic and OpenAI and….)?

Second, investors should consider the timing of the broader capital markets landscape.

Google's parent company recently announced plans to raise approximately $80–85 billion in equity capital to fund AI infrastructure expansion. 

Today, Meta announced similar plans to raise capital by issuing stock. 

This is because the debt markets have been tapped. They can't raise any more money with bond offerings. 

Around the same period, SpaceX is seeking roughly $75 billion. 

Meanwhile, Anthropic and OpenAI are each expected to seek ENORMOUS amounts of additional capital in the coming months.

Collectively, these transactions represent hundreds of billions of dollars competing for investor attention and liquidity within a relatively short time frame.

Litquidity is making no bones about it when he calls it: a “cataclysmic exit liquidity avalanche.” 

Does this ring any bells?

“Because Bubble…” - The Big Short. 

So let’s ask:

• Is there enough capital available to absorb all of these offerings at current valuations?

• Are these companies competing for the same pool of institutional capital?

• Could earlier raises reduce demand for later raises? 

Now… What’s Up with Berkshire?

Another concern is the broader backdrop in which this offering is arriving. Take a look and see Barchart throwing his two cents in:

In case you missed it, that says “the stock market has never been richer over more than 100 years.”

Several widely followed valuation measures suggest U.S. equities are trading at historically extreme levels. The Shiller CAPE ratio has reached levels seen only during the late-1990s dot-com bubble, while the Buffett Indicator (total stock market value relative to GDP) has recently reached or approached record highs. Depending on the metric used, today's market is trading at valuation levels that rival or exceed some of the most expensive periods in U.S. financial history.

At the same time, Berkshire Hathaway has been moving in the opposite direction.

That should be reread.

Berkshire is socking cash away - Darth Powell hits the nail on the head:

Fire selling. 

One of the most successful investment firms in the world is selling virtually all of their exposure to the consumer. 

That’s right. While investors chase AI, space, and infrastructure opportunities, The company was a net seller of approximately $173 billion of stocks from 2022 through 2024 and accumulated a record cash position that reached nearly $400 billion in 2026. Berkshire's buyback activity also largely disappeared during 2025 before resuming on a limited basis in 2026 (cite).

In sum, its cash and Treasury holdings have reached all-time highs.

Of course, Berkshire's actions do not guarantee a market decline. Warren Buffett and Berkshire have often appeared early, rather than wrong. Nevertheless, investors should ask:

• Why is one of the most successful investment organizations in history holding nearly $400 billion in cash while public investors are rushing into highly valued growth opportunities?

• If valuations are as attractive as many market participants believe, why has Berkshire been a persistent net seller?

• Are today's investors underwriting future growth, or are they underwriting future expectations that may already be reflected in current prices?

• If hundreds of billions of dollars of new equity issuance are coming from Google, SpaceX, Anthropic, OpenAI, and other AI-related ventures, will there be enough incremental capital to support all of them at current valuations?

What’s Up with ME?

I’m treading lightly. I wrapped up most of my positions on Friday and I’m holding tight but looking for opportunities in the midst of the uncertainty. (Look out for invitations to the WAR ROOM when I’m live to bring your questions - JW is live every day so don’t be shy.)

But in sum… the combination of record market valuations, unprecedented capital raising, and Berkshire Hathaway's historically defensive positioning does not necessarily mean a correction is imminent. It does, however, suggest investors should approach these offerings with perhaps more skepticism than enthusiasm.

As always, To YOUR success… and stay sharp out there!

Attio is the AI CRM for high-growth teams.

Connect your email, calls, product data and more, and Attio instantly builds your CRM with enriched data and complete context. Whether you’re running product-led growth or enterprise sales, Attio adapts to your unique GTM motion.

Then Ask Attio to plan your next move.

Run deep web research on prospects. Update your pipeline as you work. Find customers and draft outreach emails. Powered by Universal Context, Attio's intelligence layer, Attio searches, updates, and creates across your data to accelerate your workflow.

Ask more from your CRM.

Ask Attio

​

*together with Stock Market Media

Happy weekend — it’s Kenny Glick here. Thank you to Jeff for letting me reach out to you with some perspective,

About two years ago, I started telling anyone who would listen that we were in the early stages of a full-blown industrial revolution.

Space. Rockets. Robots. Quantum. AI. Chips.

Most people nodded politely and went back to arguing about interest rates.

I kept saying it anyway - because I could see it on the tape. 

The volume was there. The sector money flows were there. The names I was putting on the watchlist every morning were moving in ways that didn't happen unless something structural was shifting underneath the market.

I gave the room NVTS at $5. It's been trading near $31. VICR went from $56 to $340. SOXL went from $7 to $240. RMBS went from $105 to $160 after what people called "bad earnings." 

ATOM went from $5 to $10. 

These are names from sectors that institutional money has been systematically accumulating for two years.

Now CNBC is running segments on it. The op-eds are catching up. Everyone has a thesis about AI and the industrial revolution.

That's fine. I don't need the credit.

What I want you to understand is this: knowing the thesis doesn't make you money.

Watching NVIDIA trigger a $350 billion options-implied price swing on earnings doesn't tell you what to do the next morning when the money rotates out of semis and into drones. 

Or out of drones and into space names. Or out of space names and into quantum.

That rotation is happening every single morning in my Hit the Bid room.

On May 27th, after 58 straight days of semiconductors going higher, the money started rotating out. SOXS gave us a long setup - entry at $5.73, risking 12 cents per share, stock ran to $6.37. Meanwhile the broader tape pivoted to drones. 

UMAC, SIDU, LUNR, MNTS - the watchlist already had every one of these names on it before the rotation started.

I am not a futurist. I do not make decade-long predictions and wait to be proven right.

I am a trader who sits in front of a screen every morning at 8:00 AM and watches where the money is going today. 

The industrial revolution thesis is the backdrop. The VWAP lines are where the actual trades happen.

You don't need to know which sector wins the next ten years.

You need to know which sector the money is flowing into this morning - and where the institutional positioning is setting up on the 1-minute chart.

That's what I do. 

That's what I teach. And that's exactly what I'm going to walk through live on Tuesday, June 9th at 1:00 PM EST.

It's a free training. 

You just need to add it to your calendar and show up.

>> Register here for the June 9th free live session.

Kenny Glick | The Warlock

P.S. If you can’t join live, please don’t worry. I’ve worked with Jeff and Davis to ensure you receive a recording. This way, you can review everything I’m doing and the education paired with at anytime, at your convenience. I’ll just need to know where to send it to you. Complete this free form, and I’ll do the rest.

*contains promoted content

Hey Folks, Jeff Bishop here,

While most traders were busy watching Wednesday's selloff, I was digging into a biotech that just received an important FDA clearance.

But before I get to that...

It's worth noting that even as the broader market struggled yesterday, two of my tactical trade ideas surged as much as 19% and 57% intraday, respectively. Here’s how the latter one looked at the close:

That's why I spend so much time searching for company-specific catalysts.

The biggest winners often don't care what the market is doing.

And that's what led me to today's idea…

What first caught my eye was the buying.

On Monday, the company's CEO purchased more than 72,000 shares on the open market.

A director bought another 75,000 shares.

There’s no better “tell” than when insiders start writing checks with their own money.

After all, nobody knows more about what's happening behind the scenes than the people running the company.

The more I dug, the more interesting this story became…

This company is developing a potential cancer treatment unlike anything currently on the market.

Most cancer therapies either attack cancer cells directly… or they help the immune system recognize and fight cancer.

This treatment is designed to do both.

And the early results have been impressive. In one ongoing study, the company reported disease control rates approaching 90%.

Response rates were reportedly several times higher than the standard of care.

Some patients have survived years longer than expected.

Now, the company is advancing through a pivotal Phase 3 trial while simultaneously expanding another clinical study that could support an accelerated approval pathway.

👉 Click Here To Read The Full Research Report 👈

Another thing that stood out to me...

Many small biotech companies constantly struggle to raise money. That can create a major overhang for shareholders.

But just in March, this company raised $33 million from healthcare-focused investors.

And management has stated that the funding is expected to carry its pivotal Phase 3 study through completion.

In other words, one of the biggest concerns investors typically have with developmental biotech companies may already be addressed.

Of course, no clinical-stage biotech is a sure thing…

Drug development is risky. Clinical trials can disappoint. And investors should always do their own due diligence.

But when I see insider buying...

Promising clinical data...

Fresh regulatory momentum...

Major studies underway...

And several potential catalysts still ahead...

I take notice.

Click here to see why this small biotech is on my watchlist today.

We'll see what happens from here.

But I wanted to make sure you had a chance to look at this story before the opening bell.

To Your Success,

P.S. -⚡Don’t miss this! 

TAKE YOUR SEAT HERE!

(ALL are welcome - Join the best trading community today!)

​

*together with Option Pit

Hey Folks, happy hump day! Jeff Bishop here.  

Great session today with my friend Mark Sebastian. He debuted PROJECT NEXT to us. Super cool but if you missed it, no worries.  Here’s his pitch. (You’ll need the password: 1dte).  

Listen, my trading radar has been up for quite some time now, as I see pretty BIG signs that the market has been becoming increasingly speculative and detached from fundamentals.

In other words… wildly OVERHEATED (imho of course).

Just consider the example of the CBRS IPO a couple of weeks ago that I recently wrote about, calling it on day 2 “one of the clearest examples of peak market enthusiasm we’ve seen in years.” 

That stock was labeled a “can’t lose” trade, and investors were tripping over each other to buy shares in the hot IPO.

While the initial valuation was around $75/share… the stock hit $380 within minutes of the opening trade.

Folks, the $75 price was already what the bankers decided was a “lofty valuation.”

The market couldn't care less, and sent the price 400% higher on the “can’t lose” mentality.

Well, seems like CBRS “could lose,” and the stock dropped nearly 50% at one point since the IPO, wiping out billions of dollars from stock bettors. 

Another GREAT recent example of traders losing their minds is Victoria's Secret. 

Yes, the lingerie company you know at the mall.

The company changed its ticker symbol from VSCO to VSXY on June 2 as part of a branding initiative emphasizing its return to a "sexy" brand identity. 

You can read the company’s press release HERE. (I’m not an affiliate, just a fan! 😉)

The ticker change itself had no impact on the company's underlying business, cash flows, assets or competitive position – Yet the stock surged nearly 50% in a single day and added roughly $2 billion of market capitalization. 

While the company also reported strong earnings and raised guidance, the timing and attention surrounding the new "VSXY" ticker helped fuel a wave of retail enthusiasm and social-media-driven speculation. 

Multiple commentators immediately compared the move to meme-stock behavior and noted that the ticker itself became part of the investment narrative.

This is the type of market behavior typically seen in late-stage bull markets: investors increasingly reward stories, branding, and momentum rather than focusing solely on fundamentals. When a company can create billions of dollars in market value while simultaneously rebranding its ticker to something more marketable, it raises questions about whether sentiment is becoming the dominant driver of prices.

Other signs of overheating include:

• Elevated valuations across many growth and AI-related stocks despite already optimistic earnings expectations.

• Increased retail participation in highly speculative names.

• Strong performance concentrated in narrative-driven sectors where investors appear willing to overlook traditional valuation metrics.

• Growing evidence that short squeezes and momentum flows are amplifying price movements well beyond what changes in intrinsic value would suggest.

None of this means the market is about to crash. However, periods when branding decisions, ticker changes, and social-media excitement can move billions of dollars are often associated with increased speculative excess and heightened risk.

Take a second to let me know your thoughts in this poll:

Anyways, look out for my next editorial. I’ll reveal what sectors I think are especially overheated as well as how I plan to trade them. 

To YOUR success,

PS. Don’t forget to give Mark’s Tilt Trades your full consideration. This PAGE shows when the next Tilt Trade is set to drop. Try it complimentary for the next 14 days while the offer is still on the table!

​

*together with Option Pit

Good morning!

Thank you for being a valued member of Bullseye Trades. I’ll be LIVE this morning (11AM EST) with my friend Mark Sebastian.

»>CLICK TO JOIN LIVE«<

We’ll be running down ALL our best trading ideas and setups.

Join us for free and come say HI!

P.S. Mark will be giving us a special debut of “tilt trades” in his PROJECT NEXT for us. Try it out for the next two weeks!

*together with NanoViricides

NNVC Just Snagged Major FDA Validation for Measles and Now This Low-Key Biotech Is Starting to Look Like a High-Upside Antiviral Contender Right as Virus Fears Heat Back Up Globally!

NanoViricides (NYSE: NNVC) is stepping into a powerful spotlight after landing FDA Orphan Drug Designation for its antiviral NV-387 targeting measles—a move that instantly elevates the story from speculative to strategically significant. 

With measles cases resurging and no approved antiviral treatments currently available, this designation does more than add credibility—it opens the door to faster development timelines, financial incentives, and potential market exclusivity. 

In a market that reacts quickly to FDA-driven momentum, this kind of news can be a serious attention magnet. In a market that reacts fast to FDA milestones, NNVC just checked a major box!

What makes this even more compelling is that NV-387 isn’t a one-virus play—it’s designed as a broad-spectrum antiviral, potentially tackling RSV, influenza, coronaviruses, Mpox, and more. 

 This isn’t just about one virus—NNVC’s platform is built to take on multiple viral threats with a single approach. That gives NNVC exposure to multiple billion-dollar opportunities with a single platform, all while Phase II trials begin to push the science closer to real-world validation. 

Take a closer look at how NNVC could be capitalizing on the growing urgency around measles and beyond and why this FDA news could be a catalyst for growth

*contains promoted content

Hey Folks, Jeff Bishop here,

Stocks kicked off the week at fresh all-time highs again on Monday as AI momentum kept fueling the market rally.

The Nasdaq and S&P 500 both closed at record levels, while traders piled back into technology after another wave of excitement surrounding Nvidia and the broader AI trade.

But while just about everything has been moving up since the initial Iran ceasefire, I’ve been especially focused on outsized movers.

And one stock that definitely fits the bill is a small biotech that has rocketed 29% over the past five trading days. 🚀

👉 Click Here To See Today’s Tactical Trade Idea 👈

This company is developing a cancer immunotherapy designed to selectively infect tumor cells and activate the body’s immune system against cancer.

In plain English, management believes it can help the immune system recognize and attack cancers that are notoriously difficult to treat.

And lately, the data coming out has been turning heads.

Over the last month alone, the company has released clinical results showing response rates that were 2x to 3x better than historical standards across multiple gastrointestinal cancers.

One trial in pancreatic cancer showed a 69% response rate.

Another colorectal cancer study demonstrated a 19.5-month median duration of response, several times higher than historical benchmarks.

And in anal cancer, the company says its treatment produced response rates nearly 2.5 times higher than the only currently approved therapy.

👉 Click Here To Read The Full Breakdown 👈

The FDA recently aligned with the company on a pivotal registration study that could potentially support both accelerated approval and full approval — a major milestone for any small biotech.

The company has also received two FDA Fast Track designations, which can help speed up the review process for treatments targeting serious unmet medical needs.

Meanwhile, several major pharma companies are already involved in collaborations tied to the program, including Roche, Pfizer, Merck Serono, and Incyte.

And just yesterday, the company announced new preclinical findings showing even stronger anti-tumor activity when its therapy was combined with RAS inhibitors, opening the door to a potentially massive new treatment strategy in pancreatic and colorectal cancer.

Momentum appears to be building quickly here…

👉 Click Here To See Why Traders Are Watching This Story Closely 👈

Despite all of these developments, the company is still trading at a level where even Wall Street’s average analyst target implies substantial upside from current prices.

Biotech momentum can move extremely fast once traders lock onto a story, especially when multiple catalysts start stacking on top of each other.

I’ll be watching this one very closely today.

To Your Success,

P.S. -⚡Daily Action in our Momentum Stock Trading Room from 9am - 4pm ET  

(ALL are welcome - FREE!!! Join the best trading community today!)

*contains promoted content

Hey Folks, Jeff Bishop here.

Traders were still buzzing over the weekend after another record-setting week for the market.

The Nasdaq, S&P 500, and Dow all pushed to fresh all-time highs Friday as AI momentum kept powering tech stocks higher.

Dell exploded nearly 33% after crushing earnings and raising guidance, while stocks tied to the AI infrastructure boom kept ripping across the board.

Right now, the market is rewarding companies connected to artificial intelligence, automation, defense tech, and next-generation infrastructure.

That’s exactly why I’m watching today’s tactical trade idea so closely.

And after Friday’s tactical trade ideas surged as high as 14% intraday, my sights are on the next under-the-radar momentum setup.

This company is building things that sounds straight out of science fiction: AI-powered battlefield systems… autonomous ground vehicles… drone interception tech… radar that can reportedly see through walls, underground, underwater, and through poor visibility conditions.

And unlike many speculative AI companies, this one has already completed live-fire testing overseas under real operational conditions.

👉 Click Here To See Today’s Tactical Trade Idea 👈

The company says its proprietary AI engine can process data directly on-site in real time, reducing the latency problems that slow down traditional defense systems.

In simple terms, management believes legacy defense tech is becoming outdated, and they’re trying to build the next-generation replacement stack.

The company has been very aggressive in 2026.

Since March alone, it has:

• Closed a major AI video intelligence acquisition valued at around $60 million

• Signed a term sheet tied to a NASDAQ-listed computer vision company

• Expanded deeper into autonomous drones and battlefield robotics

• Secured its first commercial defense order in Latin America

• Announced a major public showcase at one of the world’s premier defense expos in Paris

The company is assembling a full AI-driven defense ecosystem piece by piece.

And traders have already shown they’re willing to chase this story aggressively.

From Thursday to Friday, the stock has ripped 24% on huge volume.

👉 Click Here To Read The Full Breakdown 👈

Another thing worth considering is that one of its subsidiaries is tied to composite components used in systems connected to Iron Dome and other missile defense infrastructure.

I’ll be watching closely to see whether traders continue rotating into smaller AI and defense names after the massive move we’ve seen in mega-cap tech.

Click here to take a closer look before the opening bell.

To Your Success,

P.S. -⚡Daily Action in our Momentum Stock Trading Room from 9am - 4pm ET  

(ALL are welcome - FREE!!! Join the best trading community today!)

​

Hey Guys & Gals,

Jeff Williams here!

I want you to try a quick mental exercise today…

Think about the monthly price you would comfortably pay to get your hands on a professional, high-conviction trade plan every single Monday morning.

Now, I want you to look at the visual below. 

It shows the maximum potential return for most of the Weekly Wiretaps alerts I've issued this year.

Note: Peak trading results are based on Jeff's target entry as specified in his trade plan, calculated using the potential best exit at the highs of the trade. Trade plans may be modified up until execution. These figures do not represent Jeff's personal, realized profits unless otherwise noted. Options trade in a wide range from opening to expiry, and exact profits vary. Trading is difficult; results are not guaranteed and should not be expected to be replicated.

Recently, we’ve had a massive 1010% potential on AMD. AMZN at 551%. Nokia for a 53% potential move.

And this past Monday, there was Ford with a 249% potential move.  

*Note: Trading is hard, results not guaranteed and should not be expected to be replicated typically.

When you compare the massive potential upside of just one of these trades to the monthly price you had in your head, the math becomes incredibly obvious. 

When you have the power to literally name your own price, the risk-to-reward ratio shifts entirely in your favor.

And remember, you aren't just getting an “alert.”

You are getting the Friday Base Camp sessions where we learn the ins-and-outs of options basics. 

You are getting the Master Guide to Options Trading video course. You are getting an environment designed to help you understand the market.

The only real risk is waking up tomorrow, seeing the market move, and realizing you missed another golden opportunity because you hesitated.

Click below to name your price before the next pick is released:

Cheers,

P.S. Tomorrow morning at 9 AM ET, I am sending out my next alert. The window to get in before the bell is closing.